Antiphospholipid syndrome and anticoagulation quality: a clinical challenge
- 1 January 2016
- journal article
- research article
- Published by Elsevier in Atherosclerosis
- Vol. 244, 48-50
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Inadequate anticoagulation by Vitamin K Antagonists is associated with Major Adverse Cardiovascular Events in patients with atrial fibrillationInternational Journal of Cardiology, 2015
- Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patientsAnnals of the Rheumatic Diseases, 2015
- The Pathogenesis of the Antiphospholipid SyndromeNew England Journal of Medicine, 2013
- Vitamin K antagonists and time in the therapeutic range: implications, challenges, and strategies for improvementJournal of Thrombosis and Thrombolysis, 2013
- Evidence-Based Management of Anticoagulant TherapyChest, 2012
- Comparison of Outcomes Among Patients Randomized to Warfarin Therapy According to Anticoagulant ControlArchives of internal medicine (1960), 2007
- Management of Antiphospholipid Antibody SyndromeJAMA, 2006
- International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)Journal of Thrombosis and Haemostasis, 2006
- A randomized clinical trial of high‐intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS)Journal of Thrombosis and Haemostasis, 2005
- A Comparison of Two Intensities of Warfarin for the Prevention of Recurrent Thrombosis in Patients with the Antiphospholipid Antibody SyndromeNew England Journal of Medicine, 2003